Company Overview
Company Type: Public Company
Website: www.alphacognition.com
Number of Employees: -
Ticker: ACOG (CNSX)
Year Founded: 2000


Business Description
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
43.4
EBITDA
(14.7)
Total Enterprise Value
43.3
TEV/EBITDA
NM
EBIT
(14.8)
Cash & ST Invst.
1.7
P/Diluted EPS Before Extra
NM
Net Income
(14.9)
Total Debt
1.6
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
2.6
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
Revenue (mm)
-
0.00
0.00
-
-
EBITDA (mm)
-
-
(3.00)
-
-

Forward Multiples (Current FY)

TEV/EBITDA
NM

Non-Periodic Estimates

Recommendation
Hold (3.00)
Target Price
1.00
Potential Upside
119.78%


Key Professionals
Name
Title
McFadden, Michael E.
CEO & Director
Cawkell, Kenneth Anthony
Founder, Special Advisor, Corporate Secretary & Director
Kalkofen, Donald A.
Chief Financial Officer
D’Angelo, Lauren 
Chief Operating Officer
Kay, Denis G.
Chief Scientific Officer
Johns, Colleen 
Senior Vice President of Product Development

Key Board Members
Name
Title
Mertz, Len P.
Independent Chairman
McFadden, Michael E.
CEO & Director
Cawkell, Kenneth Anthony
Founder, Special Advisor, Corporate Secretary & Director
Galvin, James E.
Chair of Scientific Advisory Board
Bakshi, Rajeev K.
Independent Director
Conidi, Frank 
Member of Scientific Advisory Board
Cummings, Jeffrey L.
Member of Scientific Advisory Board
Havens, John 
Independent Director
Mertz, Phillip 
Independent Director
Peskind, Elaine 
Member of Scientific Advisory Board
Sano, Mary 
Member of Scientific Advisory Board
Yaffe, Kristine 
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
301–1228 Hamilton Street | Vancouver, BC | V6B 6L2 | Canada
Phone: 604-564-9244   

Current and Pending Investors
Manchester Management Company, LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.46
Market Cap (mm)
46.0
Open
 0.43
Shares Out. (mm)
101.1
Previous Close
 0.46
Float %
75.5%
Change on Day
0.03
Shares Sold Short (mm)
-
Change % on Day
5.8%
Dividend Yield %
-
Day High/Low
 0.46/ 0.43
Diluted EPS Excl. Extra Items
(0.19)
52 wk High/Low
 0.55/ 0.19
P/Diluted EPS Before Extra
NM
Volume (mm)
0.03
Avg 3M Dly Vlm (mm)
0.04
Beta 5Y
2.99


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
CNSX:ACOG - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Crystal Bridge Enterprises Inc.
As of March 18, 2021, Crystal Bridge Enterprises Inc. was acquired by AlphaCognition, Inc., in a reverse merger transaction. Crystal Bridge Enterprises Inc. does not have significant operations. It intends to identify and evaluate assets or businesses with a view to completing a qualifying transaction. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

United States and Canada
Asset Management and Custody Banks
-
1.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-31-2023
-
Private Placement
Target
Alpha Cognition Inc. (CNSX:ACOG)


5.20
Aug-31-2023
Aug-31-2023
Private Placement
Target
Alpha Cognition Inc. (CNSX:ACOG)


1.35
May-30-2023
-
Private Placement
Target
Alpha Cognition Inc. (CNSX:ACOG)


6.50
Feb-09-2023
Mar-16-2023
Private Placement
Target
Alpha Cognition Inc. (CNSX:ACOG)
Manchester Management Company, LLC

4.40
Nov-17-2022
-
Public Offering
Target
Alpha Cognition Inc. (CNSX:ACOG)


7.44
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-27-2023
Product-Related Announcements
Alpha Cognition Inc. Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
Aug-31-2023
Private Placements
Alpha Cognition Inc. announced that it expects to receive $5.2 million in funding
Aug-31-2023
Private Placements
Alpha Cognition Inc. announced that it has received $1.345093 million in funding
Aug-14-2023
Product-Related Announcements
Alpha Cognition Inc. Receives Notice of Allowance for U.S. Patent Application Covering Use of ALPHA-1062 for Mild to Moderate Alzheimer's Disease
Jun-27-2023
Annual General Meeting
Alpha Cognition Inc., Annual General Meeting, Jun 27, 2023

M&A Advisors
Sui & Company


Advisors
Most Recent Auditor
Manning Elliott LLP
M&A Advisors
Sui & Company
Private Placement Advisors
Echelon Wealth Partners Inc., Haywood Securities Inc., Raymond James Ltd., Spartan Capital Securities, LLC
Public Offering Advisors
Manning Elliott LLP, Morton Law LLP


Most Recent Auditor
Manning Elliott


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
ValuEngine, Inc.

Oct 02, 2023 02:43 AM
ACOG
ValuEngine Rating and Forecast Report for ACOGF
Reports
11
Raymond James Ltd.
Sarugaser, Rahul
Sep 28, 2023 01:20 PM
ACOG
ACOG | At Last, NDA for ALPHA-1062 Submitted to US FDA | Mid-2024 Approval, Should All Go Smoothly
Notes
9
Zacks Small-Cap Research
Vandermosten, John D.
Feb 14, 2023 11:00 AM
ACOG
Obtaining Capital
Reports
6
Raymond James Ltd.
Sarugaser, Rahul
Feb 09, 2023 10:30 AM
ACOG
ACOG | $7 mln Raise = Painful Dil'n, But Lives to Fight Another Day: Enables NDA | Cut to $1.00, MP3
EPS Estimates*
9
Zacks Small-Cap Research
Vandermosten, John D.
Dec 06, 2022 01:01 PM
ACOG
Seeking Capital
Reports
10
iA Capital Markets
Stellick, Chelsea
Nov 29, 2022 07:30 AM
ACOG
ACOG Faces Funding Shortfall in Q3/22
Notes
5
Raymond James Ltd.
Sarugaser, Rahul
Oct 04, 2022 05:25 AM
ACOG
ACOG | Biogen's Lecanamab Data Positive for ACOG | Readthrough
Reports
9
Zacks Small-Cap Research
Vandermosten, John D.
Sep 02, 2022 07:03 AM
ACOG
Bioequivalence Complete
Reports
11
Raymond James Ltd.
Sarugaser, Rahul
Aug 31, 2022 11:25 AM
ACOG
ACOG | 2Q22: NDA App. Strengthened | Trim TP to $3 on Cash Need for RESOLVE | Maint. Convict'n + OP2
Notes
9
iA Capital Markets
Stellick, Chelsea
Aug 26, 2022 01:20 AM
ACOG
ACOG Met Key Milestones in Q2/22
Notes
5


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Manchester Management Company, LLC

9,483,568

9.38

4.2

May-15-2023


Havens, John 

5,708,482

5.65

2.5

Jun-08-2023


Cawkell B.A., LL.B., Kenneth Anthony

5,361,899

5.31

2.4

Jun-08-2023


Mertz, Len P.

3,444,390

3.41

1.5

Jun-08-2023


Mertz Holdings

2,512,033

2.49

1.1

May-15-2023


Bakshi B.B.A., Rajeev K.

296,079

0.29

0.1

May-15-2023


Mertz, Phillip 

269,910

0.27

0.1

Jun-08-2023


McFadden, Michael E.

220,166

0.22

0.1

Jun-08-2023


Kalkofen B.A., Donald A.

10,000

0.01

0.0

Jun-08-2023



 


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
ALPHA-0602 (Future), ALPHA-0702 (Future), ALPHA-0802 (Future), Alpha-1062 (Future)


Upcoming Events
Date/Time
Type
Nov-24-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-27-2023
-
Alpha Cognition Inc. (CNSX:ACOG)
SEDAR
News Releases
138 KB
Aug-31-2023
-
Alpha Cognition Inc. (CNSX:ACOG)
SEDAR
News Releases
232 KB
Aug-31-2023
-
Alpha Cognition Inc. (CNSX:ACOG)
SEDAR
Material Change Report
71 KB
Aug-23-2023
-
Alpha Cognition Inc. (CNSX:ACOG)
SEDAR
News Releases
228 KB
Aug-22-2023
-
Alpha Cognition Inc. (CNSX:ACOG)
SEDAR
News Releases
299 KB
Aug-22-2023
Jun-30-2023
Alpha Cognition Inc. (CNSX:ACOG)
SEDAR
Interim Financial Statements
630 KB
Aug-14-2023
-
Alpha Cognition Inc. (CNSX:ACOG)
SEDAR
News Releases
185 KB
Jun-08-2023
-
Alpha Cognition Inc. (CNSX:ACOG)
SEDAR
News Releases
154 KB
Jun-08-2023
-
Alpha Cognition Inc. (CNSX:ACOG)
SEDAR
News Releases
199 KB
May-30-2023
-
Alpha Cognition Inc. (CNSX:ACOG)
SEDAR
Management Proxy Materials
73 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Kalkofen B.A., Donald A. (Chief Financial Officer)
May-13-2022 - May-16-2022
Common Shares
10,000
7,149
Open Market Acquisition
New
Multiple
-
May-13-2022
Common Shares
2,500
1,786
Open Market Acquisition
-
Exchange Announcement
-
May-16-2022
Common Shares
2,500
1,820
Open Market Acquisition
-
Exchange Announcement
-
May-16-2022
Common Shares
5,000
3,543
Open Market Acquisition
-
Exchange Announcement
Havens, John  (Independent Director)
Jan-18-2022 - Jan-21-2022
Common Shares
33,138
39,229
Open Market Acquisition
0.58
Multiple
-
Jan-21-2022
Common Shares
1,000
1,164
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
100
124
Open Market Acquisition
-
Exchange Announcement
-
Jan-21-2022
Common Shares
2,124
2,435
Open Market Acquisition
-
Exchange Announcement
-
Jan-21-2022
Common Shares
5,743
6,756
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
100
123
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
100
123
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
100
122
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
200
246
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
300
370
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
300
295
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
1,000
1,174
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
1,886
2,198
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
1,900
2,344
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
2,000
2,377
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
2,614
3,164
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
3,100
3,820
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
8,300
10,262
Open Market Acquisition
-
Exchange Announcement
-
Jan-18-2022
Common Shares
2,271
2,131
Open Market Acquisition
-
Exchange Announcement
Havens, John  (Independent Director)
Dec-09-2021 - Dec-13-2021
Common Shares
79,000
105,586
Open Market Acquisition
1.41
Multiple
-
Dec-09-2021
Common Shares
20,000
26,944
Open Market Acquisition
-
Exchange Announcement
-
Dec-13-2021
Common Shares
10,500
13,992
Open Market Acquisition
-
Exchange Announcement
-
Dec-13-2021
Common Shares
5,200
6,955
Open Market Acquisition
-
Exchange Announcement
-
Dec-13-2021
Common Shares
11,300
15,213
Open Market Acquisition
-
Exchange Announcement
-
Dec-13-2021
Common Shares
492
624
Open Market Acquisition
-
Exchange Announcement
-
Dec-13-2021
Common Shares
500
645
Open Market Acquisition
-
Exchange Announcement
-
Dec-13-2021
Common Shares
1,600
2,046
Open Market Acquisition
-
Exchange Announcement
-
Dec-13-2021
Common Shares
7,400
9,544
Open Market Acquisition
-
Exchange Announcement
-
Dec-13-2021
Common Shares
4,300
5,593
Open Market Acquisition
-
Exchange Announcement
-
Dec-13-2021
Common Shares
2,100
2,761
Open Market Acquisition
-
Exchange Announcement
-
Dec-13-2021
Common Shares
600
780
Open Market Acquisition
-
Exchange Announcement
-
Dec-13-2021
Common Shares
2,000
2,665
Open Market Acquisition
-
Exchange Announcement
-
Dec-13-2021
Common Shares
13,008
17,825
Open Market Acquisition
-
Exchange Announcement
Havens, John  (Independent Director)
Dec-08-2021
Common Shares
49,200
64,238
Open Market Acquisition
0.89
Multiple
Mertz, Len P. (Independent Chairman)
Nov-09-2021
Common Shares
1,025,000
563,238
Derivative Exercise and Retained Stock
42.37
Multiple
-
Nov-09-2021
Common Shares
625,000
343,438
Derivative Exercise and Retained Stock
-
Exchange Announcement
-
Nov-09-2021
Common Shares
400,000
219,800
Derivative Exercise and Retained Stock
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Mertz, Len P.
Independent Chairman
604-564-9244
-

McFadden, Michael E.
CEO & Director
604-564-9244
-
mmcfadden@alphacognition.com
Cawkell, Kenneth Anthony
Founder, Special Advisor, Corporate Secretary & Director
1-604-619-0990
-
kcawkell@neurodyn.ca
Galvin, James E.
Chair of Scientific Advisory Board
604-564-9244
-

Bakshi, Rajeev K.
Independent Director
604-761-2100
-

Conidi, Frank 
Member of Scientific Advisory Board
604-564-9244
-

Cummings, Jeffrey L.
Member of Scientific Advisory Board
604-564-9244
-

Havens, John 
Independent Director
604-564-9244
-
jhavens@seismicexchange.com
Mertz, Phillip 
Independent Director
604-564-9244
-

Peskind, Elaine 
Member of Scientific Advisory Board
604-564-9244
-

Sano, Mary 
Member of Scientific Advisory Board
604-564-9244
-

Yaffe, Kristine 
Member of Scientific Advisory Board
604-564-9244
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
McFadden, Michael E.
CEO & Director
604-564-9244
-
mmcfadden@alphacognition.com
Cawkell, Kenneth Anthony
Founder, Special Advisor, Corporate Secretary & Director
1-604-619-0990
-
kcawkell@neurodyn.ca
Kalkofen, Donald A.
Chief Financial Officer
604-564-9244
-

D’Angelo, Lauren 
Chief Operating Officer
604-564-9244
-

Kay, Denis G.
Chief Scientific Officer
604-564-9244
-
dgkay@neurodyn.ca
Johns, Colleen 
Senior Vice President of Product Development
604-564-9244
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
